{"database":"ecrin-mdr-crc","file_versions":[],"scores":null,"additional":{"omics_type":["Clinical"],"study_start_year":["2005"],"condition":["Adenocarcinoma","Colorectal Cancer","Metastases"],"disease":["Adenocarcinoma","Colorectal Cancer","Metastases"],"study_type":["Interventional"],"full_dataset_link":["https://newmdr.ecrin.org/Study/2012161"],"location":["United States"],"study_start_month":["1"],"keyword":["Metastatic Colorectal Adenocarcinoma","Anti TAG-72","Monoclonal Antibody"],"repository":["ECRIN MDR"],"study_status":["Terminated"],"additional_accession":[]},"is_claimable":false,"name":"Safety and Activity of 90Y-Labeled IDEC-159 in Subjects With Metastatic Colorectal Adenocarcinoma","description":"This is a Phase I/II open-label, dose-escalating study in patients with metastatic colorectal cancer. The objectives of the study are to obtain information on the safety of radiolabeled IDEC-159, as well as its activity in colorectal cancer. Another objective is to determine the maximum tolerated dose (MTD). The study duration is 2 years with visits occuring daily and/or weekly for the first 3 months, and every 6 weeks until the end of the 2 year period.","dates":{"creation":"2005-01-15"},"accession":"2012161","cross_references":{"ClinicalTrials___gov":["NCT00102024"]}}